You can use a stock screen and look at clinical stage(no revenue) biotechs and most of them don't have anywhere near the indications or as as far along in approval / vetting process as CYDY yet 90% of them are trading substantially higher than CYDY. If we could get off the OTC we would be trading $3-17 per share at the stage we are. Maybe substantially more considering all of the indications we have.